Advances in peptide-based human papillomavirus therapeutic vaccines

Current Topics in Medicinal Chemistry

Volumn 12, Issue 14, 2012, Pages 1581-1592

  Liu, Tzu Yu ^a   Hussein, Waleed M ^a   Toth, Istvan ^a   Skwarczynski, Mariusz ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anticancer vaccine; Cervical cancer; HPV 16; Human papillomavirus; Peptide subunit vaccine; Therapeutic vaccine

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERLEUKIN 18; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONTANIDE ISA 51; NANOPARTICLE; PEPTIDE VACCINE; PHOSPHORYL LIPID A; PLASMID DNA; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E6; PROTEIN E6[43-57]; PROTEIN E7; PROTEIN E7[11-20]; PROTEIN E7[12-20]; PROTEIN E7[44-62]; PROTEIN E7[86-93]; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; WART VIRUS VACCINE;

CANCER CONTROL; CELLULAR IMMUNITY; DELAYED HYPERSENSITIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INFECTION CONTROL; LIPOSOMAL DELIVERY; MUCOSAL IMMUNITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CELL INTERACTION; VULVA CANCER; VULVAL INTRAEPITHELIAL NEOPLASIA; WART VIRUS;

HUMANS; IMMUNOTHERAPY, ACTIVE; MICROBIAL SENSITIVITY TESTS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, SUBUNIT;

EID: 84866949240     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612802652402     Document Type: Review

References (126)

1. Schiffman, M.; Castle, P.E.; Jeronimo, J.; Rodriguez, A.C.; Wacholder, S., Human papillomavirus and cervical cancer. Lancet, 2007, 370(9590), 890-907.
2. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P., Global cancer statistics, 2002. CA. Cancer J. Clin., 2005, 55(2), 74-108.
3. Munoz, N.; Bosch, F.X.; de Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K.V.; Snijders, P.J.; Meijer, C.J., Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med., 2003, 348(6), 518-527.
4. Bosch, F.X.; Manos, M.M.; Munoz, N.; Sherman, M.; Jansen, A.M.; Peto, J.; Schiffman, M.H.; Moreno, V.; Kurman, R.; Shah, K.V., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst., 1995, 87(11), 796-802.
5. Eiben, G.L.; da Silva, D.M.; Fausch, S.C.; Le Poole, I.C.; Nishimura, M.I.; Kast, W.M., Cervical cancer vaccines: recent advances in HPV research. Viral Immunol., 2003, 16(2), 111-121.
6. Da Silva, D.M.; Eiben, G.L.; Fausch, S.C.; Wakabayashi, M.T.; Rudolf, M.P.; Velders, M.P.; Kast, W.M., Cervical cancer vaccines: emerging concepts and developments. J. Cell. Physiol., 2001, 186(2), 169-182.
7. Robinson, W., 3rd, Management of cervical neoplasia. Cancer Treat. Res., 2001, 104, 287-302.
8. Harper, D.M.; Franco, E.L.; Wheeler, C.M.; Moscicki, A.B.; Romanowski, B.; Roteli-Martins, C.M.; Jenkins, D.; Schuind, A.; Costa Clemens, S.A.; Dubin, G., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 2006, 367(9518), 1247-1255.
9. Future II Study Group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med., 2007, 356(19), 1915-1927.
10. Paavonen, J.; Jenkins, D.; Bosch, F.X.; Naud, P.; Salmeron, J.; Wheeler, C.M.; Chow, S.N.; Apter, D.L.; Kitchener, H.C.; Castellsague, X.; de Carvalho, N.S.; Skinner, S.R.; Harper, D.M.; Hedrick, J.A.; Jaisamrarn, U.; Limson, G.A.; Dionne, M.; Quint, W.; Spiessens, B.; Peeters, P.; Struyf, F.; Wieting, S.L.; Lehtinen, M.O.; Dubin, G., Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 2007, 369(9580), 2161-2170.
11. Frazer, I.H.; Leggatt, G.R.; Mattarollo, S.R., Prevention and treatment of papillomavirus-related cancers through immunization. Annu. Rev. Immunol., 2011, 29, 111-138.
12. Trimble, C.L.; Frazer, I.H., Development of therapeutic HPV vaccines. Lancet Oncol, 2009, 10(10), 975-980.
13. Su, J.H.; Wu, A.; Scotney, E.; Ma, B.; Monie, A.; Hung, C.F.; Wu, T.C., Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs, 2010, 24(2), 109-129.
14. Hung, C.F.; Ma, B.; Monie, A.; Tsen, S.W.; Wu, T.C., Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin. Biol. Ther., 2008, 8(4), 421-439.
15. Hildesheim, A.; Herrero, R.; Wacholder, S.; Rodriguez, A.C.; Solomon, D.; Bratti, M.C.; Schiller, J.T.; Gonzalez, P.; Dubin, G.; Porras, C.; Jimenez, S.E.; Lowy, D.R., Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA, 2007, 298(7), 743-753.
16. Chen, J.; Ni, G.; Liu, X.S., Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell. Immunol., 2011, 269(1), 5-9.
17. Lepique, A.P.; Rabachini, T.; Villa, L.L., HPV vaccination: the beginning of the end of cervical cancer?-A Review. Mem. Inst. Oswaldo Cruz, 2009, 104(1), 1-10.
18. Govan, V.A., Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes. Ann. N. Y. Acad. Sci., 2005, 1056, 328-343.
19. Frazer, I.H., Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol., 2004, 4(1), 46-54.
20. Khazaie, K.; Bonertz, A.; Beckhove, P., Current developments with peptide-based human tumor vaccines. Curr. Opin. Oncol., 2009, 21(6), 524-530.
21. Skwarczynski, M.; Zaman, M.; Urbani, C.N.; Lin, I.C.; Jia, Z.F.; Batzloff, M.R.; Good, M.F.; Monteiro, M.F.; Toth, I., Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew. Chem. Int. Ed. Engl., 2010, 49(33), 5742-5745.
22. Skwarczynski, M.; Toth, I., Peptide-based subunit nanovaccines. Curr Drug Deliv, 2011, 8(3), 282-289.
23. Zinkernagel, R.M.; Doherty, P.C., Restriction of in vitro T cellmediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature, 1974, 248(450), 701-702.
24. Parmiani, G.; Castelli, C.; Dalerba, P.; Mortarini, R.; Rivoltini, L.; Marincola, F.M.; Anichini, A., Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst., 2002, 94(11), 805-818.
25. Purcell, A.W.; McCluskey, J.; Rossjohn, J., More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov., 2007, 6(5), 404-414.
26. Buteau, C.; Markovic, S.N.; Celis, E., Challenges in the development of effective peptide vaccines for cancer. Mayo Clin. Proc., 2002, 77(4), 339-349.
27. Cid-Arregui, A., Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol. J., 2009, 3, 67-83.
28. Yugawa, T.; Kiyono, T., Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol, 2009, 19(2), 97-113.
29. zur Hausen, H., Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer, 2002, 2(5), 342-350.
30. Romanczuk, H.; Howley, P.M., Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc. Natl. Acad. Sci. USA, 1992, 89(7), 3159-3163.
31. Dyson, N.; Howley, P.M.; Munger, K.; Harlow, E., The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 1989, 243(4893), 934-937.
32. Werness, B.A.; Levine, A.J.; Howley, P.M., Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 1990, 248(4951), 76-79.
33. Jabbar, S.F.; Abrams, L.; Glick, A.; Lambert, P.F., Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res., 2009, 69(10), 4407-4414.
34. Frazer, I.H., Immunology of papillomavirus infection. Curr. Opin. Immunol., 1996, 8(4), 484-491.
35. Insinga, R.P.; Perez, G.; Wheeler, C.M.; Koutsky, L.A.; Garland, S.M.; Leodolter, S.; Joura, E.A.; Ferris, D.G.; Steben, M.; Brown, D.R.; Elbasha, E.H.; Paavonen, J.; Haupt, R.M., Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol. Biomarkers Prev., 2010, 19(6), 1585-1594.
36. Carter, J.J.; Koutsky, L.A.; Wipf, G.C.; Christensen, N.D.; Lee, S.K.; Kuypers, J.; Kiviat, N.; Galloway, D.A., The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis., 1996, 174(5), 927-936.
37. Carter, J.J.; Koutsky, L.A.; Hughes, J.P.; Lee, S.K.; Kuypers, J.; Kiviat, N.; Galloway, D.A., Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis., 2000, 181(6), 1911-1919.
38. Carter, J.J.; Madeleine, M.M.; Shera, K.; Schwartz, S.M.; Cushing-Haugen, K.L.; Wipf, G.C.; Porter, P.; Daling, J.R.; McDougall, J.K.; Galloway, D.A., Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res., 2001, 61(5), 1934-1940.
39. Ling, M.; Kanayama, M.; Roden, R.; Wu, T.C., Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J. Biomed. Sci., 2000, 7(5), 341-356.
40. Konya, J.; Dillner, J., Immunity to oncogenic human papillomaviruses. Adv. Cancer Res., 2001, 82, 205-238.
41. Arany, I.; Tyring, S.K.; Stanley, M.A.; Tomai, M.A.; Miller, R.L.; Smith, M.H.; McDermott, D.J.; Slade, H.B., Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res., 1999, 43(1), 55-63.
42. Nicholls, P.K.; Moore, P.F.; Anderson, D.M.; Moore, R.A.; Parry, N.R.; Gough, G.W.; Stanley, M.A., Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology, 2001, 283(1), 31-39.
43. Roden, R.B.; Ling, M.; Wu, T.C., Vaccination to prevent and treat cervical cancer. Hum. Pathol., 2004, 35(8), 971-982.
44. Halpert, R.; Fruchter, R.G.; Sedlis, A.; Butt, K.; Boyce, J.G.; Sillman, F.H., Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet. Gynecol., 1986, 68(2), 251-258.
45. Laga, M.; Icenogle, J.P.; Marsella, R.; Manoka, A.T.; Nzila, N.; Ryder, R.W.; Vermund, S.H.; Heyward, W.L.; Nelson, A.; Reeves, W.C., Genital papillomavirus infection and cervical dysplasia--opportunistic complications of HIV infection. Int. J. Cancer, 1992, 50(1), 45-48.
46. Schafer, A.; Friedmann, W.; Mielke, M.; Schwartlander, B.; Koch, M.A., The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am. J. Obstet. Gynecol., 1991, 164(2), 593-599.
47. Hopfl, R.; Heim, K.; Christensen, N.; Zumbach, K.; Wieland, U.; Volgger, B.; Widschwendter, A.; Haimbuchner, S.; Muller-Holzner, E.; Pawlita, M.; Pfister, H.; Fritsch, P., Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet, 2000, 356(9246), 1985-1986.
48. Gabrilovich, D.I.; Velders, M.P.; Sotomayor, E.M.; Kast, W.M., Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol., 2001, 166(9), 5398-5406.
49. Sheu, B.C.; Hsu, S.M.; Ho, H.N.; Lien, H.C.; Huang, S.C.; Lin, R.H., A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res., 2001, 61(1), 237-242.
50. Cella, M.; Sallusto, F.; Lanzavecchia, A., Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol., 1997, 9(1), 10-16.
51. Hart, D.N., Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 1997, 90(9), 3245-3287.
52. Steinman, R.M., The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 1991, 9, 271-296.
53. Cella, M.; Engering, A.; Pinet, V.; Pieters, J.; Lanzavecchia, A., Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature, 1997, 388(6644), 782-787.
54. Pierre, P.; Turley, S.J.; Gatti, E.; Hull, M.; Meltzer, J.; Mirza, A.; Inaba, K.; Steinman, R.M.; Mellman, I., Developmental regulation of MHC class II transport in mouse dendritic cells. Nature, 1997, 388(6644), 787-792.
55. Austyn, J.M., New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med., 1996, 183(4), 1287-1292.
56. Tindle, R.W., Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer, 2002, 2(1), 59-65.
57. Natale, C.; Giannini, T.; Lucchese, A.; Kanduc, D., Computerassisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol. Cell Biol., 2000, 78(6), 580-585.
58. Matthews, K.; Leong, C.M.; Baxter, L.; Inglis, E.; Yun, K.; Backstrom, B.T.; Doorbar, J.; Hibma, M., Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J. Virol., 2003, 77(15), 8378-8385.
59. Tay, S.K.; Jenkins, D.; Maddox, P.; Campion, M.; Singer, A., Subpopulations of Langerhans' cells in cervical neoplasia. Br. J. Obstet. Gynaecol., 1987, 94(1), 10-15.
60. Cho, Y.S.; Kang, J.W.; Cho, M.; Cho, C.W.; Lee, S.; Choe, Y.K.; Kim, Y.; Choi, I.; Park, S.N.; Kim, S.; Dinarello, C.A.; Yoon, D.Y., Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett., 2001, 501(2-3), 139-145.
61. Ronco, L.V.; Karpova, A.Y.; Vidal, M.; Howley, P.M., Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev., 1998, 12(13), 2061-2072.
62. Nees, M.; Geoghegan, J.M.; Hyman, T.; Frank, S.; Miller, L.; Woodworth, C.D., Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol., 2001, 75(9), 4283-4296.
63. Lee, S.J.; Cho, Y.S.; Cho, M.C.; Shim, J.H.; Lee, K.A.; Ko, K.K.; Choe, Y.K.; Park, S.N.; Hoshino, T.; Kim, S.; Dinarello, C.A.; Yoon, D.Y., Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J. Immunol., 2001, 167(1), 497-504.
64. Barnard, P.; McMillan, N.A., The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology, 1999, 259(2), 305-313.
65. Barnard, P.; Payne, E.; McMillan, N.A., The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology, 2000, 277(2), 411-419.
66. Park, J.S.; Kim, E.J.; Kwon, H.J.; Hwang, E.S.; Namkoong, S.E.; Um, S.J., Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem., 2000, 275(10), 6764-6769.
67. Le Buanec, H.; Lachgar, A.; D'Anna, R.; Zagury, J.F.; Bizzini, B.; Bernard, J.; Ittele, D.; Hallez, S.; Giannouli, C.; Burny, A.; Zagury, D., Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein. Biomed. Pharmacother., 1999, 53(7), 323-328.
68. Straight, S.W.; Herman, B.; McCance, D.J., The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol., 1995, 69(5), 3185-3192.
69. Campo, M.S., Animal models of papillomavirus pathogenesis. Virus Res., 2002, 89(2), 249-261.
70. Thomsen, P.; van Deurs, B.; Norrild, B.; Kayser, L., The HPV16 E5 oncogene inhibits endocytic trafficking. Oncogene, 2000, 19(52), 6023-6032.
71. Daneri-Navarro, A.; Del Toro-Arreola, S.; Sanchez-Hernandez, P.E.; Ramirez-Duenas, M.G.; Armendariz-Borunda, J.; Perez-Montfort, R., Immunosuppressive activity of proteases in cervical carcinoma. Gynecol. Oncol., 2005, 98(1), 111-117.
72. Ibrahim, R.; Frederickson, H.; Parr, A.; Ward, Y.; Moncur, J.; Khleif, S.N., Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer, 2006, 106(5), 1065-1077.
73. Heusinkveld, M.; Welters, M.J.; van Poelgeest, M.I.; van der Hulst, J.M.; Melief, C.J.; Fleuren, G.J.; Kenter, G.G.; van der Burg, S.H., The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int. J. Cancer, 2011, 128(2), 379-389.
74. Welters, M.J.; Kenter, G.G.; de Vos van Steenwijk, P.J.; Lowik, M.J.; Berends-van der Meer, D.M.; Essahsah, F.; Stynenbosch, L.F.; Vloon, A.P.; Ramwadhdoebe, T.H.; Piersma, S.J.; van der Hulst, J.M.; Valentijn, A.R.; Fathers, L.M.; Drijfhout, J.W.; Franken, K.L.; Oostendorp, J.; Fleuren, G.J.; Melief, C.J.; van der Burg, S.H., Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced Tcell responses. Proc. Natl. Acad. Sci. USA, 2010, 107(26), 11895-11899.
75. Oldenhove, G.; de Heusch, M.; Urbain-Vansanten, G.; Urbain, J.; Maliszewski, C.; Leo, O.; Moser, M., CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J. Exp. Med., 2003, 198(2), 259-266.
76. Nakanishi, Y.; Lu, B.; Gerard, C.; Iwasaki, A., CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature, 2009, 462(7272), 510-513.
77. Padilla-Paz, L.A., Human papillomavirus vaccine: history, immunology, current status, and future prospects. Clin. Obstet. Gynecol., 2005, 48(1), 226-240.
78. Kanodia, S.; Da Silva, D.M.; Kast, W.M., Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int. J. Cancer, 2008, 122(2), 247-259.
79. Alvarez-Salas, L.M.; DiPaolo, J.A., Molecular approaches to cervical cancer therapy. Curr Drug Discov Technol, 2007, 4(3), 208-219.
80. Howley, P.M.; Munger, K.; Romanczuk, H.; Scheffner, M.; Huibregtse, J.M., Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses. Princess Takamatsu Symp., 1991, 22, 239-248.
81. Crook, T.; Morgenstern, J.P.; Crawford, L.; Banks, L., Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJras. EMBO J., 1989, 8(2), 513-519.
82. Jochmus-Kudielka, I.; Schneider, A.; Braun, R.; Kimmig, R.; Koldovsky, U.; Schneweis, K.E.; Seedorf, K.; Gissmann, L., Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J. Natl. Cancer Inst., 1989, 81(22), 1698-1704.
83. Ahn, W.S.; Bae, S.M.; Kim, T.Y.; Kim, T.G.; Lee, J.M.; Namkoong, S.E.; Kim, C.K.; Sin, J.I., A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum. Gene Ther., 2003, 14(15), 1389-1399.
84. Kim, S.W.; Yang, J.S., Human papillomavirus type 16 E5 protein as a therapeutic target. Yonsei Med. J., 2006, 47(1), 1-14.
85. Chen, Y.F.; Lin, C.W.; Tsao, Y.P.; Chen, S.L., Cytotoxic-Tlymphocyte human papillomavirus type 16 E5 peptide with CpGoligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice. J. Virol., 2004, 78(3), 1333-1343.
86. Stoler, M.H.; Rhodes, C.R.; Whitbeck, A.; Wolinsky, S.M.; Chow, L.T.; Broker, T.R., Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol., 1992, 23(2), 117-128.
87. Velders, M.P.; Markiewicz, M.A.; Eiben, G.L.; Kast, W.M., CD4+ T cell matters in tumor immunity. Int. Rev. Immunol., 2003, 22(2), 113-140.
88. Pardoll, D.M., Cancer vaccines. Nat. Med., 1998, 4(5 Suppl), 525-531.
89. Schoenberger, S.P.; Toes, R.E.; van der Voort, E.I.; Offringa, R.; Melief, C.J., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 1998, 393(6684), 480-483.
90. Stohlman, S.A.; Bergmann, C.C.; Lin, M.T.; Cua, D.J.; Hinton, D.R., CTL effector function within the central nervous system requires CD4+ T cells. J. Immunol., 1998, 160(6), 2896-2904.
91. von Herrath, M.G.; Yokoyama, M.; Dockter, J.; Oldstone, M.B.; Whitton, J.L., CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol., 1996, 70(2), 1072-1079.
92. Ressing, M.E.; Sette, A.; Brandt, R.M.; Ruppert, J.; Wentworth, P.A.; Hartman, M.; Oseroff, C.; Grey, H.M.; Melief, C.J.; Kast, W.M., Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol., 1995, 154(11), 5934-5943.
93. Kast, W.M.; Brandt, R.M.; Drijfhout, J.W.; Melief, C.J., Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J. Immunother. Emphasis Tumor Immunol., 1993, 14(2), 115-120.
94. Alexander, M.; Salgaller, M.L.; Celis, E.; Sette, A.; Barnes, W.A.; Rosenberg, S.A.; Steller, M.A., Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol., 1996, 175(6), 1586-1593.
95. Feltkamp, M.C.; Smits, H.L.; Vierboom, M.P.; Minnaar, R.P.; de Jongh, B.M.; Drijfhout, J.W.; ter Schegget, J.; Melief, C.J.; Kast, W.M., Vaccination with cytotoxic T lymphocyte epitopecontaining peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 1993, 23(9), 2242-2249.
96. Feltkamp, M.C.; Vreugdenhil, G.R.; Vierboom, M.P.; Ras, E.; van der Burg, S.H.; ter Schegget, J.; Melief, C.J.; Kast, W.M., Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol., 1995, 25(9), 2638-2642.
97. Tindle, R.W.; Fernando, G.J.; Sterling, J.C.; Frazer, I.H., A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA, 1991, 88(13), 5887-5891.
98. Vambutas, A.; DeVoti, J.; Nouri, M.; Drijfhout, J.W.; Lipford, G.B.; Bonagura, V.R.; van der Burg, S.H.; Melief, C.J., Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine, 2005, 23(45), 5271-5280.
99. Bijker, M.S.; van den Eeden, S.J.; Franken, K.L.; Melief, C.J.; Offringa, R.; van der Burg, S.H., CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J. Immunol., 2007, 179(8), 5033-5040.
100. Zwaveling, S.; Ferreira Mota, S.C.; Nouta, J.; Johnson, M.; Lipford, G.B.; Offringa, R.; van der Burg, S.H.; Melief, C.J., Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol., 2002, 169(1), 350-358.
101. Kenter, G.G.; Welters, M.J.; Valentijn, A.R.; Lowik, M.J.; Berends-van der Meer, D.M.; Vloon, A.P.; Drijfhout, J.W.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; van der Burg, S.H.; Melief, C.J., Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer. Res., 2008, 14(1), 169-177.
102. Welters, M.J.; Kenter, G.G.; Piersma, S.J.; Vloon, A.P.; Lowik, M.J.; Berends-van der Meer, D.M.; Drijfhout, J.W.; Valentijn, A.R.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; Melief, C.J.; van der Burg, S.H., Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer. Res., 2008, 14(1), 178-187.
103. Kenter, G.G.; Welters, M.J.; Valentijn, A.R.; Lowik, M.J.; Berends-van der Meer, D.M.; Vloon, A.P.; Essahsah, F.; Fathers, L.M.; Offringa, R.; Drijfhout, J.W.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; van der Burg, S.H.; Melief, C.J., Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med., 2009, 361(19), 1838-1847.
104. Moyle, P.M.; Olive, C.; Ho, M.F.; Pandey, M.; Dyer, J.; Suhrbier, A.; Fujita, Y.; Toth, I., Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J. Med. Chem., 2007, 50(19), 4721-4727.
105. van Driel, W.J.; Ressing, M.E.; Kenter, G.G.; Brandt, R.M.; Krul, E.J.; van Rossum, A.B.; Schuuring, E.; Offringa, R.; Bauknecht, T.; Tamm-Hermelink, A.; van Dam, P.A.; Fleuren, G.J.; Kast, W.M.; Melief, C.J.; Trimbos, J.B., Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer, 1999, 35(6), 946-952.
106. Ressing, M.E.; van Driel, W.J.; Brandt, R.M.; Kenter, G.G.; de Jong, J.H.; Bauknecht, T.; Fleuren, G.J.; Hoogerhout, P.; Offringa, R.; Sette, A.; Celis, E.; Grey, H.; Trimbos, B.J.; Kast, W.M.; Melief, C.J., Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother., 2000, 23(2), 255-266.
107. Muderspach, L.; Wilczynski, S.; Roman, L.; Bade, L.; Felix, J.; Small, L.A.; Kast, W.M.; Fascio, G.; Marty, V.; Weber, J., A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer. Res., 2000, 6(9), 3406-3416.
108. Moyle, P.M.; Toth, I., Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem., 2008, 15(5), 506-516.
109. Zaman, M.; Abdel-Aal, A.B.; Phillipps, K.S.; Fujita, Y.; Good, M.F.; Toth, I., Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine, 2010, 28(10), 2243-2248.
110. Zhong, W.; Skwarczynski, M.; Toth, I., Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery. Aust. J. Chem., 2009, 62(9), 956-967.
111. Skwarczynski, M.; Toth, I., Lipid-core-peptide system for selfadjuvanting synthetic vaccine delivery. Methods Mol. Biol., 2011, 751, 297-308.
112. Zaman, M.; Skwarczynski, M.; Toth, I. In Dendritic Cells: Types, Life Cycles and Biological Functions. Welles, L.C., Ed.; Nova Science Publishers Inc.:New York, 2010, pp 63-80.
113. Sarkar, A.K.; Tortolero-Luna, G.; Nehete, P.N.; Arlinghaus, R.B.; Mitchell, M.F.; Sastry, K.J., Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. Viral Immunol., 1995, 8(3), 165-174.
114. Chen, W.; Huang, L., Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol. Pharm., 2008, 5(3), 464-471.
115. Torrens, I.; Mendoza, O.; Batte, A.; Reyes, O.; Fernandez, L.E.; Mesa, C.; Guillen, G., Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine, 2005, 23(50), 5768-5774.
116. Reinis, M.; Stepanek, I.; Simova, J.; Bieblova, J.; Pribylova, H.; Indrova, M.; Bubenik, J., Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int. J. Oncol., 2010, 36(3), 545-551.
117. Daftarian, P.; Mansour, M.; Benoit, A.C.; Pohajdak, B.; Hoskin, D.W.; Brown, R.G.; Kast, W.M., Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine, 2006, 24(24), 5235-5244.
118. Daftarian, P.M.; Mansour, M.; Pohajdak, B.; Fuentes-Ortega, A.; Korets-Smith, E.; Macdonald, L.; Weir, G.; Brown, R.G.; Kast, W.M., Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides. J. Transl. Med., 2007, 5, 26.
119. Tang, J.; Yin, R.; Tian, Y.; Huang, Z.; Shi, J.; Fu, X.; Wang, L.; Wu, Y.; Hao, F.; Ni, B., A novel self-assembled nanoparticle vaccine with HIV-1 Tat/HPV16 E7 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8 T cell-dependent anti-tumor immunity in mice. Vaccine, 2012, 30(6), 1071-1082.
120. Itoh, T.; Celis, E., Transcutaneous immunization with cytotoxic Tcell peptide epitopes provides effective antitumor immunity in mice. J. Immunother., 2005, 28(5), 430-437.
121. Alexander, J.; Sidney, J.; Southwood, S.; Ruppert, J.; Oseroff, C.; Maewal, A.; Snoke, K.; Serra, H.M.; Kubo, R.T.; Sette, A.; et al., Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity, 1994, 1(9), 751-761.
122. Alexander, J.; del Guercio, M.F.; Frame, B.; Maewal, A.; Sette, A.; Nahm, M.H.; Newman, M.J., Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper Tlymphocyte epitope (PADRE). Vaccine, 2004, 22(19), 2362-2367.
123. Wu, C.Y.; Monie, A.; Pang, X.; Hung, C.F.; Wu, T.C., Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. J. Biomed. Sci., 2010, 17, 88.
124. Zeng, Q.; Peng, S.; Monie, A.; Yang, M.; Pang, X.; Hung, C.F.; Wu, T.C., Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum. Gene Ther., 2011, 22(7), 809-819.
125. Manuri, P.R.; Nehete, B.; Nehete, P.N.; Reisenauer, R.; Wardell, S.; Courtney, A.N.; Gambhira, R.; Lomada, D.; Chopra, A.K.; Sastry, K.J., Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. Vaccine, 2007, 25(17), 3302-3310.
126. Steller, M.A.; Gurski, K.J.; Murakami, M.; Daniel, R.W.; Shah, K.V.; Celis, E.; Sette, A.; Trimble, E.L.; Park, R.C.; Marincola, F.M., Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer. Res., 1998, 4(9), 2103-2109.